Abstract
Purpose: To evaluate the association of a new biochemical recurrence (BCR) risk stratification system with PSMA-targeted PET/CT findings. Methods: Two prospective studies that included patients with BCR were pooled. Findings on PSMA PET were catalogued. Patients were characterized according to the European Association of Urology (EAU) BCR risk categories. Univariable and multivariable analyses were carried out by logistic regression. Results: 145 patients were included (45 low-risk and 100 high-risk). High-risk BCR patients had a higher positive rate when compared to low-risk (82.0% vs. 48.9%; P < 0.001), and reached independent predictor status for positive PSMA PET/CT scan on multivariable logistic regression (OR 6.73, 95% CI 2.41-18.76; P < 0.001). The AUC using the combination of BCR risk group and PSA was higher than PSA alone (0.834 vs. 0.759, P = 0.015). Conclusion: The EAU BCR risk group defines the best candidates who can benefit from a PSMA PET/CT scan when BCR occurs.
- Oncology: GU
- PET
- Radiopharmaceuticals
- BCR
- Prostate cancer
- positron emission tomography
- prostate-specific membrane antigen
- Copyright © 2021 by the Society of Nuclear Medicine and Molecular Imaging, Inc.